Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.51 |
| ▸ | GRK6 | P43250 | 2/20 | 0.48 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636228 | 0.87 | KAT2B (0.69) | KAT2BTSHRCYP3A4MAPTL3MBTL1 | |
| SCHEMBL6250970 | 0.86 | KAT2B (0.66) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL7466967 | 0.85 | KAT2B (0.71) | KAT2BTSHRCYP3A4MAPTL3MBTL1 | |
| SCHEMBL17819083 | 0.83 | KAT2B (0.72) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL17263168 | 0.82 | KAT2B (0.59) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL15082923 | 0.82 | MAPT (0.61) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| Iodide SCHEMBL8985633 | 0.82 | KAT2B (0.63) | KAT2BTSHRCYP3A4MAPTL3MBTL1 | |
| SCHEMBL1519080 | 0.81 | MAPT (0.57) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL7811895 | 0.81 | MAPT (0.57) | KAT2BTSHRCYP3A4MAPTMAPK1 | |
| SCHEMBL3512219 | 0.81 | MAPT (0.57) | KAT2BMAPTMAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243168-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INST (US) | 2025-07-31 | — | — | US | disclosed |
| US-12281084-B2 | Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same | THE WISTAR INSTITUTE (US) | 2025-04-22 | — | — | US | disclosed |
| US-20220281826-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE | 2022-09-08 | — | — | US | disclosed |
| CN-114466840-A | acetyl-CoA synthetase 2(ACSS2) inhibitors and methods of use thereof | 威斯达研究所 | 2022-05-10 | — | — | CN | disclosed |
| EP-3983391-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | The Wistar Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252407-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-2247580-B1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| WO-2009109258-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2003024937-A1 | BENZIMIDAZOLYLALKOXYARYL ALKANOIC ACID DERIVATIVES AND THEIR USE AS ANTIHYPERGLYCEMICS | MERCK PATENT GMBH (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-4011173-A | MODIFIED NEMATIC MIXTURES WITH POSITIVE DIELECTRIC ANISOTROPY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | KAT2B 1631/4885TSHR 396/4885CYP3A4 285/4885 |
| US-12281084-B2 | Acetyl-CoA synthetase 2 (ACSS2) inhibitors and methods using same | ACSS2, ACACB, ACACA | KAT2B 430/4885TSHR 4791/4885CYP3A4 3058/4885 |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GPR119, IAPP, GLP1R | KAT2B 4752/4885TSHR 122/4885CYP3A4 347/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | KAT2B 1631/4885TSHR 396/4885CYP3A4 285/4885 |
| US-20220281826-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | ACSS2, ACACB, ACACA | KAT2B 430/4885TSHR 4791/4885CYP3A4 3058/4885 |
| US-20250243168-A1 | ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME | ACSS2, ACACB, ACACA | KAT2B 430/4885TSHR 4791/4885CYP3A4 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.